- Home
- HALO vs ARWR Comparison
HALO vs ARWR Comparison
Compare HALO & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HALO | ARWR |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.2B |
| IPO Year | 2001 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HALO | ARWR |
|---|---|---|
| Price | $71.61 | $73.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $78.64 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $151,862,000.00 | $16,142,321.00 |
| Revenue This Year | $28.24 | N/A |
| Revenue Next Year | $12.56 | N/A |
| P/E Ratio | $58.69 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $51.06 | $14.30 |
| 52 Week High | $82.22 | $82.26 |
Technical Indicators
Market Signals| Indicator | HALO | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 46.21 |
| Support Level | $67.94 | $70.49 |
| Resistance Level | $74.58 | $77.39 |
| Average True Range (ATR) | 2.03 | 3.63 |
| MACD | 0.27 | -0.89 |
| Stochastic Oscillator | 86.63 | 26.81 |
Price Performance
Historical ComparisonAbout HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.